TDxd for treating HER2-positive breast cancer with brain and/or leptomeningeal metastases

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X about recent paper by Takahiro Nakayama et al., titled “Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)” published on Breast Cancer.

Authors: Takahiro Nakayama, Naoki Niikura, Takashi Yamanaka, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura, Yuri Ozaki, Shuji Sakai, Daisuke Takiguchi, Takehiko Takata, Armin Bastanfard, Kazuhito Shiosakai, Junji Tsurutani

“ Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) | Breast Cancer.”

Source: Elisabetta Bonzano/X